Citations

Clear

371 citation(s) found for "Cho, B".

Exome sequencing directly implicates 68 genes in inflammatory bowel disease
Zhu, Ruifei , Zhang, Qian , Yuan, Kai , Zhang, Rui , Turvey, Alexandra K. , Stevens, Christine R , Ahmad, Tariq, Bernstein, Çharles N. , Bokemeyer, Bernd , Brooks, Johanne , Butterworth, Jeffrey, Clark, Katie, Cummings, F, Ennis, Sarah, Färkkilä, M, Faubion, William A. , Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Irving, Peter, Jarvis, Mark , Johnston, EL, Karlson, Elizabeth W, Kemp, Cheryl, Kennedy, Nick, Lees, Charlie, Lewis, James D. , Li, Andy, Louis, Édouard , McGovern, Dermot P.B., Oglesby, Arabis, Perez, Kate J, Pollok, R, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Sands, Bruce, Satsangi, Jack, Schreiber, Stefan, Selinger, Christian, Shedwell, Sophy, Silverberg, M, Singh, Salil, Steel, Alan, Uhlig, H, Verma, Ajay, Vermeire, Séverine , Weersma, Rinse K. , Xavier, Ramnik, Parkes, Miles, Rioux, John D. , Anderson, Carl A. , Raine, Tim , Uhlig, Holm H. , Fachal, Laura , Bernstein, Charles Noah , Bokemeyer, Bernd , Brant, Steven R , Cho, Judy H , Duerr, Richard H , Faubion, William , Franchimont, Denis , Franke, André , Kupcinskas, Juozas , Lamb, Christopher A , Lewis, James D , Loescher, Britt-Sabina , Louis, Edouard , McCauley, Jacob L , Moayyedi, Paul , Newberry, Rodney D , Palotie, Aarno V. , Pekow, Joel , Prescott, Natalie , Sabic, Ksenija , Sands, Bruce E , Silverberg, Mark S , Sokol, Harry , Vermeire, Séverine , Weersma, Rinse K , Xavier, Ramnik J , Yu, Mingrui , Rioux, John D , Daly, Mark J. , Huang, Hailiang , Anderson, Carl A , Raine, Tim , Zhang, Qian , Yuan, Kai , Stevens, Christine R. , Fachal, Laura , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , Ennis, Sarah A. , Färkkilâ, Martti , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Karlson, Elizabeth W. , Kennedy, Nicholas Alexander , Lees, Charlie W. , McCauley, Jacob L. , McGovern, Dermot P.B. , McLaughlin, John , Moayyedi, Paul , Moran, G , Newberry, Rodney D. , Pekow, Joel , Satsangi, Jack, Sazonovs, Aleksejs , Schreiber, Stefan , Selinger, Christian P. , Steed, Helen , Parkes, Miles , Zhang, Rui

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.08.26352648 | PMID 42180385 Get It

Abstract Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
Use of Machine‐Learning Models to Identify Clinical Features Associated With A Future Clinical Worsening Event in Patients With Pulmonary Arterial Hypertension
DuBrock, Hilary M. , Tang, Xiaoqin , Doad, Gurinderpal , Lam, Jenny , Cho, Michelle , Murugadoss, Karthik , Doddahonnaiah, Deeksha , Wagner, Tyler E. , DuBrock, Hilary M , Murugadoss, Karthik , Doad, Gurinderpal , Cho, Michelle , Wagner, Tyler E

Mayo Clinic

Pulmonary Circulation | May 6, 2026 | Volume: 16 | Issue: 2 | Pages: No page available

10.1002/pul2.70294 | PMID 42099826 Get It

ABSTRACT Clinical worsening events are increasingly recognized as a meaningful outcome in pulmonary arterial hypertension (PAH). We applied machine‐learning models to real‐world data to identify clinical features that may predict clinical worsening events in PAH. Data were obtained retrospectively from the electronic health records of adults diagnosed with PAH at Mayo Clinic locations (January 2015–December 2019). Machine‐learning LASSO regularized logistic regression models were developed to analyze the association between 100 clinical features and occurrence of clinical worsening events. In total, 455 patients were included (mean age 62.1 years; 59.3% female). Of these, 232 (51.0%) experienced a clinical worsening event after a median (quartile 1, quartile 3) of 10.9 (4.1, 21.4) months. The best‐performing model had an area under the curve of 0.78, sensitivity of 78%, and specificity of 59%. The model identified 11 clinical features associated with clinical worsening events in PAH with a non‐zero coefficient: baseline age, body mass index (BMI), creatinine level, red cell (erythrocyte) distribution width (RDW), mean pulmonary arterial pressure, pulmonary vascular resistance, sodium concentration, and QT interval, along with dyspnea, number of clinic visits, and other forms of heart disease within a 1‐month window before a clinical worsening event. Baseline RDW and BMI, and number of clinic visits within the 1‐month window were statistically significantly associated with clinical worsening events. Our study used machine‐learning models to identify clinical features associated with risk of clinical worsening events in PAH. Automation of risk prediction could lead to earlier therapeutic intervention to optimize patient outcomes.
Whole Genome Sequence Analysis of Weight Loss in 16 972 Participants With COPD Reveals Novel Risk Loci in DRAIC and RFX3
Chiles, J.W. , Rocco, Alison, Srinivasasainagendra, Vinodh, Rossiter, Harry B. , Casaburi, Richard, Thalacker-Mercer, Anna, Wells, J Michael, Wan, Emily S., Silverman, Edwin K., Cho, Michael H., Hersh, Craig P., PSATY, B, Gharib, Sina A., Gao, Yan, O’Connor, George T., Lange, Leslie A., Rich, Stephen S., Manichaikul, Ani W., Barr, R. Graham, Ortega, V E, Meyers, Deborah A., Smith, Albert V., Tiwari, Hemant K., McDonald, Merry-Lynn N. , McDonald, Merry‐Lynn , Chiles, Joe W , Casaburi, Richard , Thalacker‐Mercer, Anna Elizabeth , Wells, J. Michael , Wan, Emily S. , Silverman, Edwin K. , Cho, Michael H. , Hersh, Craig P. , Psaty, Bruce M , Gharib, Sina A. , Lange, Leslie A., Rich, Stephen S. , Manichaikul, Ani , Barr, R. Graham, Meyers, Deborah A. , Tiwari, Hemant K.

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | April 24, 2026 | Volume: 17 | Issue: 3 | Pages: No page available

10.1002/jcsm.70293 | PMID 42026014 Get It

ABSTRACT Background Chronic obstructive pulmonary disease (COPD) is associated with musculoskeletal comorbidities, including cachexia. Weight loss (WL) is the major criterion for cachexia and increases risk for mortality in COPD. Risk factors for WL in COPD are incompletely understood. We performed this whole genome sequencing (WGS) analysis to identify genetic risk variants for WL in COPD. Methods We studied 16 972 participants from the Trans‐Omics for Precision Medicine (TOPMed) Initiative and All of Us Research Program. COPD was diagnosed using spirometry in TOPMed, while diagnosis codes were used in All of Us. WL was defined as WL ≥ 5% or a final body mass index (BMI) < 20 kg/m 2 . WGS data came from white blood cells in all cohorts. Single‐variant testing was conducted on both race‐ and study‐stratified cohorts and in a cosmopolitan, ancestry‐independent manner using GENESIS in TOPMed and SAIGE in All of Us. SAIGE‐GENE+ gene‐based analyses were performed on race‐stratified and cosmopolitan cohorts. Single variant meta‐analyses were conducted using METAL within (B/AA and NHW analyses of Black/African–American and non‐Hispanic white participants, respectively) and across racial groups (COSMO). Rare variant gene‐based results were combined using Fisher's method. Transcriptomic effects were predicted using MetaXcan. We used the GWAS Catalogue to analyse for colocalization with other related traits. Results Two single variants were associated with WL in COPD among All of Us participants: one intronic variant in HCN1 in Black/African–American participants (chr5:45271359:TACACAC:T, odds ratio with 95% confidence interval (OR (CI 95 )) = 2.43(1.78–3.31), p = 1.95 × 10 −8 ) and one intergenic variant between PPP4R2 and PDZRN3 in the cosmopolitan and NHW cohorts (chr3:73345901:A:G, OR (CI 95 ) = 0.21(0.12–0.35), p = 8.84 × 10 −9 in cosmopolitan and OR (CI 95 ) = 0.18(0.10–0.33), p = 9.44 × 10 −9 in NHW). Single‐variant meta‐analysis identified two loci associated with WL in COPD: five variants within DRAIC in the B/AA meta‐analysis (lead variant chr15:69571341:A:G, OR (CI 95 ) = 1.37(1.23–1.51), p = 1.29 × 10 −9 ) and two intronic variants within RFX3 in the cosmopolitan meta‐analysis (lead variant chr9:3390983:T:C, OR (CI 95 ) = 1.50(1.31–1.73), p = 1.06 × 10 −8 ). Rare variants within RNU6‐565P (NHW analysis in All of Us; p = 2.83 × 10 −7 ) and LOC339298 (B/AA analysis in All of Us, p = 1.85 × 10 −6 ) were associated with WL in COPD. The RNU‐565P signal remained significant after combination with TOPMed results (p combined = 1.23 × 10 −6 ). MetaXcan predicted differential expression of LNC00959 in visceral adipose tissue ( p = 1.16 × 10 −6 in COSMO analysis). Colocalization analyses identified genomic associations between BMI and variants in or near DRAIC , RFX3 , PDZRN3 , and LINC00959 . Conclusions In the first WGS analysis of WL in COPD, we have identified seven novel loci. Further characterization of these loci will validate our findings and improve our understanding of the molecular pathophysiology of this condition.
Long‐term hippocampal alterations and cognitive impairment in a murine model of surgical sepsis
Cho, Dong Seong , Schmitt, R. , Ducharme, Alexandra M. , Doles, Jason D. , Schmitt, Rebecca E , Ducharme, Alexandra , Doles, Jason D , Dasgupta, Aneesha

Mayo Clinic

FEBS Open Bio | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/2211-5463.70240 | PMID 41992425 Get It

Cognitive impairment in sepsis survivors is a growing clinical challenge as the number of sepsis cases rise and acute mortality rates fall. It is estimated that up to 70% of sepsis patients experience cognitive dysfunction and many report persistent dysfunction post‐sepsis. Cognitive impairment is a broad term that refers to sepsis‐associated brain dysfunction or encephalopathy (SABD or SAE, respectively). While many contributors, such as inflammation, blood–brain barrier dysfunction, and extended microglial activation are implicated in SABD/SAE development, much is still unknown regarding the underlying mechanistic causes of persistent cognitive defects in sepsis survivors. Here, we employed cecal ligation and puncture (CLP) to model surgical sepsis in mice, after which mice were subjected to multiple memory function assays for up to 2 months post‐sepsis. Furthermore, single‐cell RNA sequencing and validation studies were performed with murine hippocampi to query alterations in the brain microenvironment. Our study shows that CLP mice exhibited decreased spontaneous alternation at 4 weeks and decreases in both short‐ and long‐term recognition (at 6 weeks and 2 weeks, respectively) accompanied by substantially altered cell type makeup of the hippocampus, including hippocampal neuron and pericyte loss. Finally, transcriptional alterations in the macrophage populations implicate aberrant activation in CLP survivors. In conclusion, post‐sepsis mice exhibit reduced memory capacity and altered hippocampal cell composition and transcriptional profiles. This study and associated data set will be valuable for further investigation of the underlying pathophysiology of SABD/SAE and elucidation of potential therapeutic candidates.
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Drilon, Alexander E., Cho, B , Camidge, D Ross, Nagasaka, Misako, Besse, Benjamin, Solomon, B, Goto, Koichi , Wolf, Jürgen, Popat, Sanjay , Felip, Enriqueta, Yang, Nong, Langen, A. de, Lu, Shun, Velcheti, Vamsidhar, Lin, Andrew , Calvet, C. , Tschaika, Marina, Afsar, Salman, Yang, Haisu, Lin, Jessica J., Solomon, Benjamin , Cho, Byoung Chul , Besse, Benjamin , Drilon, Alexander , Langen, Adrianus J. de , Drilon, Alexander , Nagasaka, Misako , Besse, Benjamin , de Langen, Adrianus Johannes , Lin, Andrew L , Popat, Sanjay , Solomon, Benjamin J , Camidge, David Ross , Wolf, Jürgen , Felip, Enriqueta , Yang, Nong, Velcheti, Vamsidhar , Afsar, Salman

Mayo Clinic

The Oncologist | April 14, 2026 | Volume: 31 | Issue: 6 | Pages: No page available

10.1093/oncolo/oyag137 | PMID 41992489 Get It

Abstract Background Repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor, is approved for ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. Its side effects and safety management strategies require further characterization. Patients and Methods The safety profile of repotrectinib (treatment-emergent/related adverse events [TEAEs/TRAEs]) was established in patients who initiated treatment at the recommended dose (160 mg daily [QD] for 14 days, then 160 mg twice daily [BID]) across all cohorts of the global, multicenter phase 1/2 TRIDENT-1 study. AE management strategies were outlined. Results In 472 patients, the most common TRAEs (dizziness [58%] and dysgeusia [50%]) were likely TRK inhibition-related. Median relative dose intensity was 90%; 14% (n = 66/472) of patients did not increase their initial QD dose to BID (mostly due to CNS AEs). Rates of dizziness (median onset, 7 days) were similar in patients with/without baseline brain metastases. Dose modifications downgraded severity or resolved dizziness in 78% of patients; 58% of patients had pharmacologic intervention without dose modification. Dizziness was downgraded/resolved in 62% (n = 120/195) of patients who did not receive dose modification or pharmacologic intervention. Treatment-related cognitive impairment and weight gain occurred in 19% and 12% of patients, respectively. Treatment-emergent withdrawal pain occurred in 14% of patients (median resolution time, 2.1 weeks). Dose interruption and reduction from TRAEs occurred in 39% and 38% of patients, respectively; 10% reported later re-escalation back to 160 mg BID. Conclusion Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
Abstract 5504: CoMMpass Explorer: An interactive platform to explore clinical and genomic data from newly diagnosed multiple myeloma patients from the landmark CoMMpass observational study.
Zhang, Wanxing , Avigan, David , Vij, Ravi, Kumar, Shaji Kunnathu, Kourelis, T., Lonial, Sagar, Cho, Hearn, Vlachos, Ioannis S., Ding, Li, Mulligan, George J., Zhang, Wanxing, Acharya, Chaitanya R. , Foltz, Steven , Parekh, Samir , Vij, Ravi , Kourelis, Taxiarchis , Lonial, Sagar , Cho, Hearn, Vlachos, Ioannis S. , Gnjatic, Sacha , Bhasin, Manoj K

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5504-5504

10.1158/1538-7445.am2026-5504 Get It

Abstract The CoMMpass study (NCT01454297) is a prospective, longitudinal observational study involving 1,141 newly diagnosed multiple myeloma (NDMM) patients. Bone marrow aspirates from the study participants were collected for comprehensive molecular characterization of tumor (using bulk RNA sequencing and whole genome sequencing) and tumor immune microenvironment using 3’ single-cell RNA sequencing (scRNA-seq). To support exploration of this rich multi-omic dataset, we developed CoMMpass Explorer (CE), an intuitive interactive platform that enables real-time analysis of clinical and genomic data from CoMMpass. A central feature of CE is cohort building, where users can filter and stratify patients by clinical, genomic, and survival data elements to create custom cohorts for analysis. CE provides five main views: Overall Summary for clinical feature distribution, Kaplan-Meier curves, and multivariate Cox proportional hazards models; Mutational Profile for visualizing and comparing somatic mutations; Tumor Profile for bulk differential expression and gene set enrichment; Immune Microenvironment for comparing cell type abundance and cell cycle dynamics between cohorts using scRNA-seq data; and Pseudo-Bulk, which aggregates single-cell expression by cell type to enable cohort-level comparisons of transcriptional programs using DEseq2. CE reproduces prior CoMMpass studies, including WEE1 expression being associated with poorer progression-free survival (Simhal, et al.) and different mutation frequencies between African American and European American patients (Manojlovic, et al.). We further demonstrate CE’s utility by interrogating the 2025 Consensus Genomic Staging (CGS) risk classification system (Avet-Loiseau, et al). We compared CGS high-risk (HR, n=249) vs. CGS standard-risk (SR, n=573) patients. HR patients have significantly worse progression-free survival, overall survival, and time to second-line therapy compared with SR patients. Univariate models recapitulated expected differences in the clinical features that define CGS risk. Bulk tumor RNA-seq and ssGSEA highlighted a more proliferative and genomically unstable transcriptional program in HR group, with upregulation of angiogenesis and cell-cycle-related pathways. In the immune microenvironment, monocytes were more abundant in the SR group. Pseudo-bulk RNA-seq of plasma cells showed overexpression of ANXA1, NSD2, IGF1R, MAF and related genes in HR. CE democratizes access to the CoMMpass multi-omic resource, allowing researchers to interrogate clinical and molecular heterogeneity. By enabling hypothesis generation and replication of published results, CE serves as a valuable tool for identifying prognostic biomarkers and meaningful patterns in gene expression, mutation profiles, and the immune microenvironment. Citation Format: Wanxing Zhang, Chaitanya R. Acharya, Steven M. Foltz, David E. Avigan, Samir Parekh, Ravi Vij, Shaji Kunnathu Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis S. Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, George Mulligan. CoMMpass Explorer: An interactive platform to explore clinical and genomic data from newly diagnosed multiple myeloma patients from the landmark CoMMpass observational study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5504.
Abstract 3887: Multiple myeloma risk classification of CoMMpass using Consensus Genomic Staging identifies differences between patients with high and low African genetic ancestry.
Gout, Alexander M. , Avigan, David E., Vij, Ravi, Kumar, Shaji Kunnathu, Lonial, Sagar, Cho, Hearn, Wozniak, Katie, Cole, Craig E. , Carpten, John D. , Mulligan, George J., Foltz, Steven , Acharya, Chaitanya R. , Jin, Yuxin , Avigan, David , Vij, Ravi , Lonial, Sagar , Cho, Hearn, Keats, Jonathan J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3887-3887

10.1158/1538-7445.am2026-3887 Get It

Abstract Background: Multiple myeloma is the second most common adult blood cancer and remains incurable, despite recent advances. The IMWG/IMS recently published updated risk criteria, Consensus Genomic Staging (CGS), combining genomic events with clinical measures to identify high-risk patients (Avet-Loiseau, et al. JCO 2025). We applied CGS risk criteria to baseline samples from the Multiple Myeloma Research Foundation CoMMpass Study (NCT01454297), a prospective, longitudinal observational study that enrolled more than1100 participants between 2011-2017. Methods: We assessed patient risk following CGS criteria. Criteria 1: del(17p), with a cutoff of &gt;20% clonal fraction, and/or TP53 mutation. Criteria 2: an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32). Criteria 3: monoallelic del(1p32) along with 1q+ or biallelic del(1p32). Criteria 4: beta-2 microglobulin &gt;= 5.5 mg/L with normal creatinine. Patients meeting one or more criteria were classified as High Risk. To test if risk showed association with genetic ancestry, we grouped patients into those with high African genetic ancestry and those with low African genetic ancestry. Genetic ancestry was measured using ADMIXTURE in comparison to 1000 Genomes. Results: We evaluated the CGS risk status of 877 CoMMpass patients, finding 69.2% (573/828) to be Standard Risk (SR) and 30.8% (255/828) to be High Risk (HR). HR patients showed worse progression-free survival (median PFS 26.3 months vs. 42.5 months; log rank test, p &lt; 0.0001) and overall survival (median OS 63.9 months vs. median not reached; p &lt; 0.0001). 10.6% (91/858) of patients met Criteria 1, 10.7% (93/873) met Criteria 2, 5.6% (49/877) met Criteria 3, and 8.7% (73/835) met Criteria 4. We found 14.2% (123/867) of patients to have high African-like genetic ancestry (AFR-high) and 85.8% (744/867) to have low African-like genetic ancestry (AFR-low). We observed significantly fewer HR patients within the AFR-high group (20%, 23/115) than in the AFR-low group (32.4%, 231/712) (Fisher’s exact test, p = 0.0065). The AFR-high group met HR criteria at a lower rate across all criteria, but only with Criteria 3 was the difference significant (p-value = 0.03). Higher levels of creatinine in AFR-high patients may have impacted meeting the normal creatinine requirement of Criteria 4. Conclusions: HR patients comprise 30.8% of CoMMpass subjects and show significantly worse PFS and OS than SR patients. AFR-high patients met HR criteria at a lower rate than AFR-low patients according to the CGS criteria. Clinical trials that utilize CGS criteria to determine patient eligibility may be challenged to enroll a representative patient population, including AFR-high patients. Screening and eligibility criteria should be carefully considered to mitigate potential enrollment disparities. Citation Format: Steven M. Foltz, Chaitanya R. Acharya, Alexander Gout, Yuxin Jin, David E. Avigan, Ravi Vij, Shaji Kunnathu Kumar, Sagar Lonial, Hearn Cho, Katie Wozniak, Jonathan J. Keats, Craig Cole, John D. Carpten, George J. Mulligan. Multiple myeloma risk classification of CoMMpass using Consensus Genomic Staging identifies differences between patients with high and low African genetic ancestry [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3887.
Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research
Zdyrski, Christopher , Pawlak, Aleksandra , Nicholson, Hannah, Corbett, Megan P. , Catucci, M., Cheville, John, Cho, H, Melvin, Bryan J. , Peng, Jiayi, Saba, Corey , Hamsher, Hayden, Friedenberg, Steven G. , Mochel, Jonathan P. , Nicholson, Hannah F , Woodward, Andrew P , Douglass, Eugene , Mochel, Jonathan P , Allenspach, Karin , Zdyrski, Christopher , Pawlak, Aleksandra , Cheville, John C.

Mayo Clinic

Clinical and Translational Medicine | March 27, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1002/ctm2.70645 | PMID 41889014 Get It

Structural Basis for C 8 methylation of 23S ribosomal RNA by Cfr
Esakova, Olga , Jung, James , Lee, Hyunwook , Cho, Sung Hyun , Alumasa, John N., Schwalm, Erica L. , Bauerle, Matthew , Hafenstein, Susan , Yu, Zhiheng, Booker, Squire J. , Esakova, Olga A , Alumasa, John , Hafenstein, Susan L , Booker, Squire J , Grove, Tyler L. , Yu, Zhiheng

Mayo Clinic

No container title available | March 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.27.707579 | PMID 41867798 Get It

Abstract Cfr methylates C 8 of adenosine 2503 (A2503) in 23 S ribosomal RNA (rRNA) and will also methylate C 2 of A2503 after methylating C 8 . C 8 methylation confers resistance to more than five classes of clinically used antibiotics, highlighting it as a worrisome mechanism of antibiotic resistance. Here, we report the structure of Cfr, determined by cryogenic electron microscopy (Cryo-EM). Despite its small size (∼36 kDa), we exploit a transient protein–RNA crosslink that forms during catalysis, which requires Cys105 to resolve. Using a Cfr Cys105Ala variant and an 87-nucleotide strand of rRNA, we isolate the crosslinked species and determine its structure to 3.0 Å resolution. Notably, the 87-mer rRNA adopts an L-shaped conformation characteristic of tRNAs, rather than the conformation it assumes in the ribosome. One Sentence Summary Cryo-EM structure of Cfr, a radical S-adenosylmethionine methylase that confers antibiotic resistance
Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins
Zhang, Chengyue , He, Yixuan, Zhang, Jingzhou, Feldman, William B. , Ding, Yi , Pasaniuc, Bogdan, Chang, Diana, Chen, Qingwen , Lasky-Su, Jessica, Hecker, Julian, Tobin, Martin D., Chen, Jing , Kalra, S. , Pratte, Katherine A., Im, Hae Kyung, Wan, Emily S., Manichaikul, Ani, Silverman, Edwin K., Bowler, Russell P., Lange, Leslie A., Ortega, Victor E., Cho, Michael H., Moll, Matthew R., Konigsberg, Iain R. , Zhang, Jingzhou , Chikowore, Tinashe , Hu, Xiaowei , Paşaniuc, Bogdan , Lasky‐Su, Jessica , Tobin, Martin D. , Pratte, Katherine , Wan, Emily S. , Manichaikul, Ani , Silverman, Edwin K. , Bowler, Russell P. , Lange, Leslie A., Ortega, Victor E. , Martin, Alicia R. , Cho, Michael H. , Moll, Matt

Mayo Clinic

JCI Insight | February 19, 2026 | Volume: 11 | Issue: 7 | Pages: No page available

10.1172/jci.insight.199951 | PMID 41712304 Get It

BACKGROUND We constructed multi-trait polygenic risk scores (PRSs) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validated their performance in diverse cohorts, and identified PRS-related proteins for potential therapeutic targeting. METHODS PRSmix + , a multi-trait PRS framework, is used to train a composite PRS (PRS multi ) in COPDGene non-Hispanic White participants ( n = 6,647). Associations of PRS multi with COPD status (GOLD 2–4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American ( n = 2,466), ECLIPSE ( n = 1,858), Mass General Brigham Biobank ( n = 15,152), and All of Us ( n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRS multi and were validated with proteomic data in COPDGene ( n = 5,173) and UK Biobank ( n = 5,012). RESULTS PRSmix + selected 7 traits for PRS multi . In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects [RE] OR 1.58 [95% CI: 1.28–1.94]) and exacerbation frequency (meta-analysis RE β 0.21 [95% CI: 0.11–0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRSs that were also validated with measured protein levels in COPDGene and UK Biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include RAGE/sRAGE, IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. CONCLUSIONS Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. TRIAL REGISTRATION COPDGene: ClinicalTrials.gov NCT00608764; ECLIPSE: ClinicalTrials.gov NCT00292552.